Kanchi Patell
Internal Medicine · Cleveland, OHNPI 1538782511
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations.
Across 74 payments — averaging $42.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$416
- Seagen Inc.$343
- Pfizer$329
- AstraZeneca$290
- Johnson & Johnson$247
- E.r. Squibb & Sons, L.L.C.$197
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,86491%
- Education$2899%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $416 |
| Seagen Inc. | 4 | $343 |
| Pfizer | 6 | $329 |
| AstraZeneca | 6 | $290 |
| Johnson & Johnson(2 entities) | 4 | $247 |
| E.r. Squibb & Sons, L.L.C. | 2 | $197 |
| Beone Medicines USA, Inc. | 2 | $168 |
| Novartis | 7 | $146 |
| Merck | 4 | $139 |
| Beigene USA, Inc. | 1 | $125 |
| GSK | 2 | $107 |
| AbbVie | 4 | $89 |
| Bristol Myers Squibb | 4 | $70 |
| Tempus AI, Inc | 1 | $70 |
| Daiichi Sankyo Inc. | 3 | $66 |
| Eisai Inc. | 3 | $55 |
| Amgen | 2 | $48 |
| Genmab U.S., Inc. | 2 | $46 |
| Sanofi | 2 | $46 |
| Astellas Pharma US Inc | 1 | $25 |
| AVEO Pharmaceuticals, Inc. | 1 | $23 |
| Gilead | 1 | $20 |
| Incyte Corporation | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| ADC Therapeutics America, Inc. | 1 | $19 |
| Array Biopharma Inc | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,153 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 12 | $115 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Cleveland
- Cyrus HarrisCleveland$726K
- Marina MagreyCleveland$312K
- Joshua LonginowCleveland$241K
- Emad MansoorCleveland$219K
- Syed BukhariCleveland$165K
- Vadim KoshkinCleveland$159K
- Suresh Kumar BalasubramanianCleveland$148K
- Christine Tanaka-EspositoCleveland$123K
- Carla HarwellCleveland$75K
- Amr MohamedCleveland$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.